6.765  -0.055 (-0.81%)		10-23 11:20
Open: 6.83 High: 6.895 Volume: 51,619		Pre. Close: 6.82 Low: 6.75 Market Cap: 438(M)

Short term
Mid term
Targets	6-month :	8.05	1-year :	9.41
Resists	First :	6.9	Second :	8.05
Pivot price	6.43
Supports	First :	6.23	Second :	5.82
MAs	MA(5) :	6.7	MA(20) :	6.36
	MA(100) :	7.9	MA(250) :	10.56
MACD	MACD :	-0.1	Signal :	-0.2
%K %D	K(14,3) :	91.6	D(3) :	89.9
RSI	RSI(14): 57.2
52-week	High :	17.44	Low :	5.71

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ EOLS ] has closed below upper band by 11.6%. Bollinger Bands are 40.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	6.9 - 6.92	6.92 - 6.95
Low:	6.61 - 6.64	6.64 - 6.67
Close:	6.77 - 6.81	6.81 - 6.85

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Wed, 22 Oct 2025
Will Evolus Stock Get A Facelift As Demand For Wrinkle Erasers Rebounds? - RTTNews

Wed, 22 Oct 2025
Evolus to Report Third Quarter Financial Results on November 5, 2025 - Stock Titan

Fri, 10 Oct 2025
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Tue, 16 Sep 2025
Evolus, Inc. (NASDAQ:EOLS): When Will It Breakeven? - simplywall.st

Sun, 10 Aug 2025
Analysts Just Slashed Their Evolus, Inc. (NASDAQ:EOLS) EPS Numbers - simplywall.st

Fri, 08 Aug 2025
Analysts Have Lowered Expectations For Evolus, Inc. (NASDAQ:EOLS) After Its Latest Results - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	0 (M)
Shares Float	65 (M)
Held by Insiders	5.059e+007 (%)
Held by Institutions	11.9 (%)
Shares Short	11,630 (K)
Shares Short P.Month	0 (K)

EPS	-3.518e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	-22.3 %
Operating Margin	-20.4 %
Return on Assets (ttm)	-11.1 %
Return on Equity (ttm)	-18 %
Qtrly Rev. Growth	2.7794e+008 %
Gross Profit (p.s.)	3.55
Sales Per Share	701.54
EBITDA (p.s.)	1.79529e+008
Qtrly Earnings Growth	-1 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-41 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-24.48

Dividend	0
Forward Dividend	1.268e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.